Analyst Update: Continental Resource, Cal-Maine, Kite Pharma

Analysts adjusted their ratings on Continental Resources, Inc. (CLR), Cal-Maine Foods Inc (CALM), and Kite Pharma Inc (KITE)

May 18, 2015 at 12:16 PM
facebook twitter linkedin


Analysts are weighing in today on oil-and-gas company Continental Resources, Inc. (NYSE:CLR), egg producer Cal-Maine Foods Inc (NASDAQ:CALM), and drugmaker Kite Pharma Inc (NASDAQ:KITE). Here's a quick roundup of today's brokerage notes on CLR, CALM, and KITE.

  • Goldman Sachs has chimed in on several commodity names, including CLR -- which saw its rating boosted to "buy" from "neutral," and its price target to $60 from $46. This hasn't had much of an impact on the shares, though, which are off 0.1% at $46.95. Continental Resources, Inc. has advanced more than 22% year-to-date, but has struggled in recent weeks after getting rejected by its descending 200-day moving average. Option traders are decisively bearish toward the stock. CLR's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio checks in at 4.49 -- just 8 percentage points from a 12-month peak.

  • CALM has soared nearly 10% today -- and hit a record high of $60.39 earlier -- to trade at $60.37. Helping the shares in their upward trek is an upgrade to "overweight" from "equal weight" at Stephens. Cal-Maine Foods Inc has been on fire for some time, lifted recently by bird flu concerns. Specifically, during the past month, the equity has outperformed the broader S&P 500 Index (SPX) by almost 36 percentage points. Short sellers may be feeling the heat. More than 28% of CALM's float is sold short, which would take over two weeks to buy back, at average daily volumes.

  • KITE is down 5.6% at $47.23, after the company reported a surprise quarterly loss last Friday. To make matters worse, Jefferies trimmed its price target on the security to $83 from $84. On the year, Kite Pharma Inc is now off roughly 18%. Despite these technical struggles, the brokerage bunch has been extremely bullish toward the shares, as all four covering analysts consider them a "strong buy." Also, KITE's consensus 12-month price target of $83.17 stands at a 76% premium to current trading levels.
 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners